{"transactions":[{"id":684100,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":22410,"kind":"person","name":"GOWER BOB G","position":1,"cik":"0001136466","reported_name":"GOWER BOB G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant","published_at":"2026-08-18T10:06:07.000Z","date":"2026-04-23","kind":"exercise","planned":false,"acquired":true,"shares":254307,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Amendment and conversion, without payment of additional consideration, of two senior convertible promissory notes, aggregate principal amount $216,000, issued in 2023 into 254,307 shares of common stock as reported in Table 1 above and a warrant to purchase 254,307 shares of common stock as reported in Table II above. In April 2026, the outstanding principal amount, together with accrued and unpaid interest, was $246,169."}],"balance_after":289836,"derivative":{"exercise_price":0.484,"exercise_date":"2026-04-23","expiration_date":"2028-04-23","underlying":"Common Stock","underlying_shares":254307},"source":{"system":"sec-edgar","filing":"0001493152-26-038866","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1136466/000149315226038866/ownership.xml","form_type":"4"}},{"id":684099,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":22410,"kind":"person","name":"GOWER BOB G","position":1,"cik":"0001136466","reported_name":"GOWER BOB G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-18T10:06:07.000Z","date":"2026-08-07","kind":"purchase","planned":false,"acquired":true,"shares":400000,"price":0.495,"value":198000.0,"ownership":{"direct":true},"balance_after":916740,"source":{"system":"sec-edgar","filing":"0001493152-26-038866","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1136466/000149315226038866/ownership.xml","form_type":"4"}},{"id":684098,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":22410,"kind":"person","name":"GOWER BOB G","position":1,"cik":"0001136466","reported_name":"GOWER BOB G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-18T10:06:07.000Z","date":"2026-04-23","kind":"purchase","planned":false,"acquired":true,"shares":508614,"price":0.484,"value":246169.176,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The total of securities reported as beneficially owned reflects two reverse stock splits effected by the Issuer subsequent to the last filing on Form 4 by the Reporting Person."}],"balance_after":516740,"source":{"system":"sec-edgar","filing":"0001493152-26-038866","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1136466/000149315226038866/ownership.xml","form_type":"4"}},{"id":1969649,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":22410,"kind":"person","name":"GOWER BOB G","position":1,"cik":"0001136466","reported_name":"GOWER BOB G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-06T21:33:15.000Z","date":"2023-03-02","kind":"purchase","acquired":true,"shares":90287,"price":0.4883,"value":44087.1421,"ownership":{"direct":true},"balance_after":1222682,"source":{"system":"sec-edgar","filing":"0001493152-23-006786","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1136466/000149315223006786/ownership.xml","form_type":"4"}},{"id":1980393,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":22410,"kind":"person","name":"GOWER BOB G","position":1,"cik":"0001136466","reported_name":"GOWER BOB G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-02T20:45:52.000Z","date":"2023-03-01","kind":"purchase","acquired":true,"shares":270000,"price":0.4777,"value":128979.0,"ownership":{"direct":true},"balance_after":1132395,"source":{"system":"sec-edgar","filing":"0001493152-23-006553","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1136466/000149315223006553/ownership.xml","form_type":"4"}},{"id":1980392,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":22410,"kind":"person","name":"GOWER BOB G","position":1,"cik":"0001136466","reported_name":"GOWER BOB G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-02T20:45:52.000Z","date":"2023-02-28","kind":"purchase","acquired":true,"shares":109300,"price":0.4883,"value":53371.19,"ownership":{"direct":true},"balance_after":862395,"source":{"system":"sec-edgar","filing":"0001493152-23-006553","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1136466/000149315223006553/ownership.xml","form_type":"4"}},{"id":2038771,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":22410,"kind":"person","name":"GOWER BOB G","position":1,"cik":"0001136466","reported_name":"GOWER BOB G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2023-02-01T23:06:45.000Z","date":"2022-12-09","kind":"grant","acquired":true,"shares":714286,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On October 28, 2022, Ensysce Biosciences, Inc. (the \"Company\"), pursuant to an amendment to the Company's Third Amended and Restated Certificate of Incorporation, effectuated a one-for-twenty reverse stock split of the Company's common stock, par value $0.0001 (the \"Common Stock\")."},{"field":"security","element":"securityTitle","label":"F3","text":"On December 9, 2022, Mr. Gower purchased 357,143 warrants to purchase 714,286 shares of Common Stock with an exercise price of $1.40 per share (the \"Warrants\") in an underwritten offering further described on the Company's Prospectus filed pursuant to Rule 424(b)(4) (File No. 333-268038) filed with the Commission on December 9, 2022. The Warrants are immediately exercisable and may be exercised until five years from the date of issuance."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On December 9, 2022, Mr. Gower purchased 357,143 warrants to purchase 714,286 shares of Common Stock with an exercise price of $1.40 per share (the \"Warrants\") in an underwritten offering further described on the Company's Prospectus filed pursuant to Rule 424(b)(4) (File No. 333-268038) filed with the Commission on December 9, 2022. The Warrants are immediately exercisable and may be exercised until five years from the date of issuance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On December 9, 2022, Mr. Gower purchased 357,143 warrants to purchase 714,286 shares of Common Stock with an exercise price of $1.40 per share (the \"Warrants\") in an underwritten offering further described on the Company's Prospectus filed pursuant to Rule 424(b)(4) (File No. 333-268038) filed with the Commission on December 9, 2022. The Warrants are immediately exercisable and may be exercised until five years from the date of issuance."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"On December 9, 2022, Mr. Gower purchased 357,143 warrants to purchase 714,286 shares of Common Stock with an exercise price of $1.40 per share (the \"Warrants\") in an underwritten offering further described on the Company's Prospectus filed pursuant to Rule 424(b)(4) (File No. 333-268038) filed with the Commission on December 9, 2022. The Warrants are immediately exercisable and may be exercised until five years from the date of issuance."}],"balance_after":716365,"derivative":{"exercise_price":1.4,"expiration_date":"2027-12-09","underlying":"Common Stock","underlying_shares":714286},"source":{"system":"sec-edgar","filing":"0001493152-23-003343","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1136466/000149315223003343/ownership.xml","form_type":"4"}},{"id":2038770,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":22410,"kind":"person","name":"GOWER BOB G","position":1,"cik":"0001136466","reported_name":"GOWER BOB G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-01T23:06:45.000Z","date":"2022-12-09","kind":"purchase","acquired":true,"shares":357143,"price":1.4,"value":500000.2,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On October 28, 2022, Ensysce Biosciences, Inc. (the \"Company\"), pursuant to an amendment to the Company's Third Amended and Restated Certificate of Incorporation, effectuated a one-for-twenty reverse stock split of the Company's common stock, par value $0.0001 (the \"Common Stock\")."},{"field":"security","element":"securityTitle","label":"F2","text":"On December 9, 2022, Mr. Gower purchased 357,143 shares of Common Stock at a price of $1.40 per share."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On December 9, 2022, Mr. Gower purchased 357,143 shares of Common Stock at a price of $1.40 per share."}],"balance_after":753095,"source":{"system":"sec-edgar","filing":"0001493152-23-003343","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1136466/000149315223003343/ownership.xml","form_type":"4"}},{"id":2221412,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":22410,"kind":"person","name":"GOWER BOB G","position":1,"cik":"0001136466","reported_name":"GOWER BOB G","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option","published_at":"2022-06-27T21:40:22.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On June 23, 2022, Mr. Gower was granted an option (the \"Stock Option\") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 23, 2022, Mr. Gower was granted an option (the \"Stock Option\") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 23, 2022, Mr. Gower was granted an option (the \"Stock Option\") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year."}],"balance_after":41585,"derivative":{"exercise_price":0.425,"expiration_date":"2032-06-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001493152-22-017876","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1136466/000149315222017876/ownership.xml","form_type":"4"}},{"id":2220841,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":125821,"kind":"person","name":"Benton Andrew","position":1,"cik":"0001867975","reported_name":"Benton Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2022-06-27T21:38:33.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On June 23, 2022, Mr. Benton was granted an option (the \"Stock Option\") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 23, 2022, Mr. Benton was granted an option (the \"Stock Option\") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 23, 2022, Mr. Benton was granted an option (the \"Stock Option\") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year."}],"balance_after":100850,"derivative":{"exercise_price":0.425,"expiration_date":"2032-06-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001493152-22-017872","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716947/000149315222017872/ownership.xml","form_type":"4"}},{"id":2220840,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":125820,"kind":"person","name":"Levin Adam","position":1,"cik":"0001868308","reported_name":"Levin Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2022-06-27T21:35:29.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On June 23, 2022, Mr. Levin was granted an option (the \"Stock Option\") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 23, 2022, Mr. Levin was granted an option (the \"Stock Option\") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 23, 2022, Mr. Levin was granted an option (the \"Stock Option\") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year."}],"balance_after":35000,"derivative":{"exercise_price":0.425,"expiration_date":"2032-06-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001493152-22-017869","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716947/000149315222017869/ownership.xml","form_type":"4"}},{"id":2220880,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":69228,"kind":"person","name":"Chang William H","position":1,"cik":"0001594408","reported_name":"Chang William H","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option","published_at":"2022-06-27T17:47:22.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On June 23, 2022, Mr. Chang was granted an option (the \"Stock Option\") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 23, 2022, Mr. Chang was granted an option (the \"Stock Option\") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 23, 2022, Mr. Chang was granted an option (the \"Stock Option\") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year."}],"balance_after":35000,"derivative":{"exercise_price":0.425,"expiration_date":"2032-06-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001493152-22-017881","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1594408/000149315222017881/ownership.xml","form_type":"4"}},{"id":2220954,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":125830,"kind":"person","name":"Martin Steven Robert","position":1,"cik":"0001328822","reported_name":"Martin Steven Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2022-06-27T17:44:36.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On June 23, 2022, Mr. Martin was granted an option (the \"Stock Option\") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 23, 2022, Mr. Martin was granted an option (the \"Stock Option\") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 23, 2022, Mr. Martin was granted an option (the \"Stock Option\") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year."}],"balance_after":100850,"derivative":{"exercise_price":0.425,"expiration_date":"2032-06-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001493152-22-017879","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328822/000149315222017879/ownership.xml","form_type":"4"}},{"id":2221277,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":125850,"kind":"person","name":"Rauch Lee M.","position":1,"cik":"0001815345","reported_name":"Rauch Lee M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2022-06-27T17:41:23.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On June 23, 2022, Ms. Rauch was granted an option (the \"Stock Option\") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 23, 2022, Ms. Rauch was granted an option (the \"Stock Option\") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 23, 2022, Ms. Rauch was granted an option (the \"Stock Option\") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year."}],"balance_after":35000,"derivative":{"exercise_price":0.425,"expiration_date":"2032-06-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001493152-22-017877","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815345/000149315222017877/ownership.xml","form_type":"4"}},{"id":2221350,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":125856,"kind":"person","name":"Rosebraugh Curtis","position":1,"cik":"0001869847","reported_name":"Rosebraugh Curtis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2022-06-27T17:38:35.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On June 23, 2022, Mr. Rosebraugh was granted an option (the \"Stock Option\") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 23, 2022, Mr. Rosebraugh was granted an option (the \"Stock Option\") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 23, 2022, Mr. Rosebraugh was granted an option (the \"Stock Option\") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year."}],"balance_after":35000,"derivative":{"exercise_price":0.425,"expiration_date":"2032-06-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001493152-22-017873","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869847/000149315222017873/ownership.xml","form_type":"4"}},{"id":2253221,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":126804,"kind":"person","name":"Kirkpatrick Lynn","position":1,"cik":"0001418785","reported_name":"Kirkpatrick Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2022-05-27T14:05:01.000Z","date":"2022-02-17","kind":"grant","acquired":true,"shares":200000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On February 17, 2022, Dr. Kirkpatrick was granted an option (the \"Stock Option\") to purchase 200,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter. The Form 4 filed February 24, 2022 included this same information for Table II except for the entry under column 9."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 17, 2022, Dr. Kirkpatrick was granted an option (the \"Stock Option\") to purchase 200,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter. The Form 4 filed February 24, 2022 included this same information for Table II except for the entry under column 9."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 17, 2022, Dr. Kirkpatrick was granted an option (the \"Stock Option\") to purchase 200,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter. The Form 4 filed February 24, 2022 included this same information for Table II except for the entry under column 9."}],"balance_after":2516939,"derivative":{"exercise_price":1.4,"expiration_date":"2032-02-17","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001493152-22-015294","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1418785/000149315222015294/ownership.xml","form_type":"4"}},{"id":2253220,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":126804,"kind":"person","name":"Kirkpatrick Lynn","position":1,"cik":"0001418785","reported_name":"Kirkpatrick Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-05-27T14:05:01.000Z","date":"2022-05-26","kind":"purchase","acquired":true,"shares":27000,"price":0.5265,"value":14215.5,"ownership":{"direct":true},"balance_after":381851,"source":{"system":"sec-edgar","filing":"0001493152-22-015294","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1418785/000149315222015294/ownership.xml","form_type":"4"}},{"id":2253219,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":126804,"kind":"person","name":"Kirkpatrick Lynn","position":1,"cik":"0001418785","reported_name":"Kirkpatrick Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-05-27T14:05:01.000Z","date":"2022-05-25","kind":"purchase","acquired":true,"shares":70000,"price":0.4869,"value":34083.0,"ownership":{"direct":true},"balance_after":354851,"source":{"system":"sec-edgar","filing":"0001493152-22-015294","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1418785/000149315222015294/ownership.xml","form_type":"4"}},{"id":2373917,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":130006,"kind":"person","name":"Birkett Kevin Geoffrey","position":1,"cik":"0001867942","reported_name":"Birkett Kevin Geoffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option","published_at":"2022-02-25T00:03:36.000Z","date":"2022-02-17","kind":"grant","acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On February 17, 2022, Mr. Birkett was granted an option (the \"Stock Option\") to purchase 50,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 17, 2022, Mr. Birkett was granted an option (the \"Stock Option\") to purchase 50,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 17, 2022, Mr. Birkett was granted an option (the \"Stock Option\") to purchase 50,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter."}],"balance_after":50000,"derivative":{"exercise_price":1.4,"expiration_date":"2032-02-17","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-22-005444","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716947/000149315222005444/ownership.xml","form_type":"4"}},{"id":2374907,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":130024,"kind":"person","name":"Humphrey David Carl","position":1,"cik":"0001708720","reported_name":"Humphrey David Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2022-02-24T19:05:03.000Z","date":"2022-02-17","kind":"grant","acquired":true,"shares":80000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On February 17, 2022, Mr. Humphrey was granted an option (the \"Stock Option\") to purchase 80,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 17, 2022, Mr. Humphrey was granted an option (the \"Stock Option\") to purchase 80,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 17, 2022, Mr. Humphrey was granted an option (the \"Stock Option\") to purchase 80,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter."}],"balance_after":80000,"derivative":{"exercise_price":1.4,"expiration_date":"2032-02-17","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001493152-22-005445","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1708720/000149315222005445/ownership.xml","form_type":"4"}},{"id":2374541,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":126804,"kind":"person","name":"Kirkpatrick Lynn","position":1,"cik":"0001418785","reported_name":"Kirkpatrick Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2022-02-24T19:00:30.000Z","date":"2022-02-17","kind":"grant","acquired":true,"shares":200000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On February 17, 2022, Dr. Kirkpatrick was granted an option (the \"Stock Option\") to purchase 200,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 17, 2022, Dr. Kirkpatrick was granted an option (the \"Stock Option\") to purchase 200,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 17, 2022, Dr. Kirkpatrick was granted an option (the \"Stock Option\") to purchase 200,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter."}],"balance_after":200000,"derivative":{"exercise_price":1.4,"expiration_date":"2032-02-17","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001493152-22-005440","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1418785/000149315222005440/ownership.xml","form_type":"4"}},{"id":2411300,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":125821,"kind":"person","name":"Benton Andrew","position":1,"cik":"0001867975","reported_name":"Benton Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2022-02-04T20:26:15.000Z","date":"2022-02-04","kind":"grant","acquired":true,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On February 4, 2022, Mr. Benton was granted an option (the \"Stock Option\") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 4, 2022, Mr. Benton was granted an option (the \"Stock Option\") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 4, 2022, Mr. Benton was granted an option (the \"Stock Option\") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022."}],"balance_after":20000,"derivative":{"exercise_price":3.13,"expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001493152-22-003220","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716947/000149315222003220/ownership.xml","form_type":"4"}},{"id":2411299,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":125820,"kind":"person","name":"Levin Adam","position":1,"cik":"0001868308","reported_name":"Levin Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2022-02-04T20:21:09.000Z","date":"2022-02-04","kind":"grant","acquired":true,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On February 4, 2022, Mr. Levin was granted an option (the \"Stock Option\") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 4, 2022, Mr. Levin was granted an option (the \"Stock Option\") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 4, 2022, Mr. Levin was granted an option (the \"Stock Option\") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022."}],"balance_after":20000,"derivative":{"exercise_price":3.13,"expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001493152-22-003213","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716947/000149315222003213/ownership.xml","form_type":"4"}},{"id":2411893,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":22410,"kind":"person","name":"GOWER BOB G","position":1,"cik":"0001136466","reported_name":"GOWER BOB G","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option","published_at":"2022-02-04T20:18:02.000Z","date":"2022-02-04","kind":"grant","acquired":true,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On February 4, 2022, Mr. Gower was granted an option (the \"Stock Option\") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 4, 2022, Mr. Gower was granted an option (the \"Stock Option\") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 4, 2022, Mr. Gower was granted an option (the \"Stock Option\") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022."}],"balance_after":20000,"derivative":{"exercise_price":3.13,"expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001493152-22-003208","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1136466/000149315222003208/ownership.xml","form_type":"4"}},{"id":2411298,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":130677,"kind":"person","name":"Pestano Linda","position":1,"cik":"0001892759","reported_name":"Pestano Linda","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option","published_at":"2022-02-04T20:16:31.000Z","date":"2022-02-04","kind":"grant","acquired":true,"shares":200000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On February 4, 2022, Ms. Pestano was granted an option (the \"Stock Option\") to purchase 200,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.01 per share, with an exercise price of $2.48. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of October 15, 2021 and the remainder in equal installments monthly for the thirty-six months thereafter."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 4, 2022, Ms. Pestano was granted an option (the \"Stock Option\") to purchase 200,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.01 per share, with an exercise price of $2.48. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of October 15, 2021 and the remainder in equal installments monthly for the thirty-six months thereafter."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 4, 2022, Ms. Pestano was granted an option (the \"Stock Option\") to purchase 200,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.01 per share, with an exercise price of $2.48. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of October 15, 2021 and the remainder in equal installments monthly for the thirty-six months thereafter."}],"balance_after":200000,"derivative":{"exercise_price":2.48,"expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001493152-22-003206","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716947/000149315222003206/ownership.xml","form_type":"4"}},{"id":2411362,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":69228,"kind":"person","name":"Chang William H","position":1,"cik":"0001594408","reported_name":"Chang William H","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option","published_at":"2022-02-04T15:24:15.000Z","date":"2022-02-04","kind":"grant","acquired":true,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On February 4, 2022, Mr. Chang was granted an option (the \"Stock Option\") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 4, 2022, Mr. Chang was granted an option (the \"Stock Option\") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 4, 2022, Mr. Chang was granted an option (the \"Stock Option\") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022."}],"balance_after":20000,"derivative":{"exercise_price":3.13,"expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001493152-22-003218","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1594408/000149315222003218/ownership.xml","form_type":"4"}},{"id":2411468,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":125830,"kind":"person","name":"Martin Steven Robert","position":1,"cik":"0001328822","reported_name":"Martin Steven Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2022-02-04T15:22:34.000Z","date":"2022-02-04","kind":"grant","acquired":true,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On February 4, 2022, Mr. Martin was granted an option (the \"Stock Option\") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 4, 2022, Mr. Martin was granted an option (the \"Stock Option\") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 4, 2022, Mr. Martin was granted an option (the \"Stock Option\") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022."}],"balance_after":20000,"derivative":{"exercise_price":3.13,"expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001493152-22-003216","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328822/000149315222003216/ownership.xml","form_type":"4"}},{"id":2411851,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":125856,"kind":"person","name":"Rosebraugh Curtis","position":1,"cik":"0001869847","reported_name":"Rosebraugh Curtis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2022-02-04T15:19:25.000Z","date":"2022-02-04","kind":"grant","acquired":true,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On February 4, 2022, Mr. Rosebraugh was granted an option (the \"Stock Option\") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 4, 2022, Mr. Rosebraugh was granted an option (the \"Stock Option\") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 4, 2022, Mr. Rosebraugh was granted an option (the \"Stock Option\") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022."}],"balance_after":20000,"derivative":{"exercise_price":3.13,"expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001493152-22-003210","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869847/000149315222003210/ownership.xml","form_type":"4"}},{"id":2411727,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":130024,"kind":"person","name":"Humphrey David Carl","position":1,"cik":"0001708720","reported_name":"Humphrey David Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2022-02-04T15:15:01.000Z","date":"2022-02-04","kind":"grant","acquired":true,"shares":275000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On February 4, 2022, Mr. Humphrey was granted an option (the \"Stock Option\") to purchase 275,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.01 per share, with an exercise price of $3.13. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 11, 2021 and the remainder in equal installments monthly for the thirty-six months thereafter."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 4, 2022, Mr. Humphrey was granted an option (the \"Stock Option\") to purchase 275,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.01 per share, with an exercise price of $3.13. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 11, 2021 and the remainder in equal installments monthly for the thirty-six months thereafter."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 4, 2022, Mr. Humphrey was granted an option (the \"Stock Option\") to purchase 275,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.01 per share, with an exercise price of $3.13. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 11, 2021 and the remainder in equal installments monthly for the thirty-six months thereafter."}],"balance_after":275000,"derivative":{"exercise_price":3.13,"expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":275000},"source":{"system":"sec-edgar","filing":"0001493152-22-003204","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1708720/000149315222003204/ownership.xml","form_type":"4"}},{"id":2645437,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":22410,"kind":"person","name":"GOWER BOB G","position":1,"cik":"0001136466","reported_name":"GOWER BOB G","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option","published_at":"2021-07-02T22:15:31.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":6585,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a \"Derivative Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a \"Derivative Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement."}],"balance_after":6585,"derivative":{"exercise_price":2.59,"expiration_date":"2029-03-14","underlying":"Common Stock","underlying_shares":6585},"source":{"system":"sec-edgar","filing":"0001192482-21-000620","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1136466/000119248221000620/edgar.xml","form_type":"4"}},{"id":2645436,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":22410,"kind":"person","name":"GOWER BOB G","position":1,"cik":"0001136466","reported_name":"GOWER BOB G","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-02T22:15:31.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":7919026,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the \"Merger Agreement\") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the \"Issuer\"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and Ensysce Biosciences, Inc., a Delaware corporation (\"Ensysce\"), Merger Sub merged with and into Ensysce (the \"Merger\"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each share of Ensysce common stock was automatically converted into the right to receive a pro rata portion of 17,334,518 shares of the Issuer's common stock."}],"balance_after":7919026,"source":{"system":"sec-edgar","filing":"0001192482-21-000620","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1136466/000119248221000620/edgar.xml","form_type":"4"}},{"id":2643508,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":125821,"kind":"person","name":"Benton Andrew","position":1,"cik":"0001867975","reported_name":"Benton Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2021-07-02T22:10:25.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":65850,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"The option vests over three years with 1/3 of the total number of shares subject to the option vesting on the first anniversary of the date of grant and 1/36th of the total number of shares subject to the option vesting monthly thereafter, until fully vested on 01/24/2023."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the \"Merger Agreement\") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the \"Issuer\"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and Ensysce Biosciences, Inc., a Delaware corporation (\"Ensysce\"), Merger Sub merged with and into Ensysce (the \"Merger\"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a \"Derivative Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the \"Merger Agreement\") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the \"Issuer\"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and Ensysce Biosciences, Inc., a Delaware corporation (\"Ensysce\"), Merger Sub merged with and into Ensysce (the \"Merger\"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a \"Derivative Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement."}],"balance_after":65850,"derivative":{"exercise_price":3.35,"expiration_date":"2030-01-23","underlying":"Common Stock","underlying_shares":65850},"source":{"system":"sec-edgar","filing":"0001192482-21-000616","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716947/000119248221000616/edgar.xml","form_type":"4"}},{"id":2643507,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":130006,"kind":"person","name":"Birkett Kevin Geoffrey","position":1,"cik":"0001867942","reported_name":"Birkett Kevin Geoffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option","published_at":"2021-07-02T22:07:31.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":329250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the \"Merger Agreement\") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the \"Issuer\"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and Ensysce Biosciences, Inc., a Delaware corporation (\"Ensysce\"), Merger Sub merged with and into Ensysce (the \"Merger\"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a \"Derivative Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the \"Merger Agreement\") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the \"Issuer\"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and Ensysce Biosciences, Inc., a Delaware corporation (\"Ensysce\"), Merger Sub merged with and into Ensysce (the \"Merger\"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a \"Derivative Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement."}],"balance_after":329250,"derivative":{"exercise_price":2.59,"expiration_date":"2029-02-28","underlying":"Common Stock","underlying_shares":329250},"source":{"system":"sec-edgar","filing":"0001192482-21-000612","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1716947/000119248221000612/edgar.xml","form_type":"4"}},{"id":2643506,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":130006,"kind":"person","name":"Birkett Kevin Geoffrey","position":1,"cik":"0001867942","reported_name":"Birkett Kevin Geoffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option","published_at":"2021-07-02T22:07:31.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":19755,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the \"Merger Agreement\") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the \"Issuer\"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and Ensysce Biosciences, Inc., a Delaware corporation (\"Ensysce\"), Merger Sub merged with and into Ensysce (the \"Merger\"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a \"Derivative Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the \"Merger Agreement\") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the \"Issuer\"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and Ensysce Biosciences, Inc., a Delaware corporation (\"Ensysce\"), Merger Sub merged with and into Ensysce (the \"Merger\"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a \"Derivative Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement."}],"balance_after":19755,"derivative":{"exercise_price":2.59,"expiration_date":"2028-10-01","underlying":"Common Stock","underlying_shares":19755},"source":{"system":"sec-edgar","filing":"0001192482-21-000612","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716947/000119248221000612/edgar.xml","form_type":"4"}},{"id":2644946,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":130024,"kind":"person","name":"Humphrey David Carl","position":1,"cik":"0001708720","reported_name":"Humphrey David Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-07-02T19:15:02.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On June 30, 2021, pursuant to that certain Agreement and Plan of Merger, dated January 31, 2021, among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the \"Issuer\"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and Ensysce Biosciences, Inc., a Delaware corporation (\"Ensysce\"), Merger Sub merged with and into Ensysce (the \"Merger\"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Upon completion of the Merger, the Reporting Person received a grant of 50,000 restricted stock units, which, subject generally to the Reporting Person's continued employment through each such date would vest as to 20,000 restricted stock units on December 15, 2021, an additional 15,000 restricted stock units on December 15, 2022, and an additional 15,000 restricted stock units on December 15, 2023."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001493152-21-016123","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1708720/000149315221016123/ownership.xml","form_type":"4"}},{"id":2643613,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":69228,"kind":"person","name":"Chang William H","position":1,"cik":"0001594408","reported_name":"Chang William H","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-02T19:14:44.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":2242189,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the \"Merger Agreement\") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the \"Issuer\"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and Ensysce Biosciences, Inc., a Delaware corporation (\"Ensysce\"), Merger Sub merged with and into Ensysce (the \"Merger\"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each share of Ensysce common stock was automatically converted into the right to receive a pro rata portion of 17,334,518 shares of the Issuer's common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents the shares held by the trusts in which the Reporting Person has sole or shared voting and dispositive power."}],"balance_after":2242189,"source":{"system":"sec-edgar","filing":"0001493152-21-016122","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1594408/000149315221016122/ownership.xml","form_type":"4"}},{"id":2643612,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":69228,"kind":"person","name":"Chang William H","position":1,"cik":"0001594408","reported_name":"Chang William H","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-02T19:14:44.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":353451,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the \"Merger Agreement\") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the \"Issuer\"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and Ensysce Biosciences, Inc., a Delaware corporation (\"Ensysce\"), Merger Sub merged with and into Ensysce (the \"Merger\"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each share of Ensysce common stock was automatically converted into the right to receive a pro rata portion of 17,334,518 shares of the Issuer's common stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Represents the shares owned jointly with the Reporting Person's wife."}],"balance_after":353451,"source":{"system":"sec-edgar","filing":"0001493152-21-016122","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1594408/000149315221016122/ownership.xml","form_type":"4"}},{"id":2644330,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":126804,"kind":"person","name":"Kirkpatrick Lynn","position":1,"cik":"0001418785","reported_name":"Kirkpatrick Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2021-07-02T18:11:57.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":6585,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a \"Derivative Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a \"Derivative Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement."}],"balance_after":6585,"derivative":{"exercise_price":2.59,"expiration_date":"2029-03-14","underlying":"Common Stock","underlying_shares":6585},"source":{"system":"sec-edgar","filing":"0001192482-21-000618","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1418785/000119248221000618/edgar.xml","form_type":"4"}},{"id":2644329,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":126804,"kind":"person","name":"Kirkpatrick Lynn","position":1,"cik":"0001418785","reported_name":"Kirkpatrick Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2021-07-02T18:11:57.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":658500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a \"Derivative Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a \"Derivative Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement."}],"balance_after":658500,"derivative":{"exercise_price":2.59,"expiration_date":"2029-02-28","underlying":"Common Stock","underlying_shares":658500},"source":{"system":"sec-edgar","filing":"0001192482-21-000618","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1418785/000119248221000618/edgar.xml","form_type":"4"}},{"id":2644328,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":126804,"kind":"person","name":"Kirkpatrick Lynn","position":1,"cik":"0001418785","reported_name":"Kirkpatrick Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2021-07-02T18:11:57.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":817560,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a \"Derivative Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a \"Derivative Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement."}],"balance_after":817560,"derivative":{"exercise_price":1.68,"expiration_date":"2028-02-05","underlying":"Common Stock","underlying_shares":817560},"source":{"system":"sec-edgar","filing":"0001192482-21-000618","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1418785/000119248221000618/edgar.xml","form_type":"4"}},{"id":2644327,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":126804,"kind":"person","name":"Kirkpatrick Lynn","position":1,"cik":"0001418785","reported_name":"Kirkpatrick Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2021-07-02T18:11:57.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":460950,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a \"Derivative Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a \"Derivative Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement."}],"balance_after":460950,"derivative":{"exercise_price":1.83,"expiration_date":"2027-01-04","underlying":"Common Stock","underlying_shares":460950},"source":{"system":"sec-edgar","filing":"0001192482-21-000618","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1418785/000119248221000618/edgar.xml","form_type":"4"}},{"id":2644326,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":126804,"kind":"person","name":"Kirkpatrick Lynn","position":1,"cik":"0001418785","reported_name":"Kirkpatrick Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2021-07-02T18:11:57.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":263400,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a \"Derivative Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a \"Derivative Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement."}],"balance_after":263400,"derivative":{"exercise_price":3.19,"expiration_date":"2026-01-15","underlying":"Common Stock","underlying_shares":263400},"source":{"system":"sec-edgar","filing":"0001192482-21-000618","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1418785/000119248221000618/edgar.xml","form_type":"4"}},{"id":2644325,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":126804,"kind":"person","name":"Kirkpatrick Lynn","position":1,"cik":"0001418785","reported_name":"Kirkpatrick Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2021-07-02T18:11:57.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":9994,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a \"Derivative Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a \"Derivative Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement."}],"balance_after":9994,"derivative":{"exercise_price":3.21,"expiration_date":"2022-12-21","underlying":"Common Stock","underlying_shares":9994},"source":{"system":"sec-edgar","filing":"0001192482-21-000618","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1418785/000119248221000618/edgar.xml","form_type":"4"}},{"id":2644324,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":126804,"kind":"person","name":"Kirkpatrick Lynn","position":1,"cik":"0001418785","reported_name":"Kirkpatrick Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2021-07-02T18:11:57.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":99950,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a \"Derivative Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a \"Derivative Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement."}],"balance_after":99950,"derivative":{"exercise_price":3.21,"expiration_date":"2022-12-01","underlying":"Common Stock","underlying_shares":99950},"source":{"system":"sec-edgar","filing":"0001192482-21-000618","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1418785/000119248221000618/edgar.xml","form_type":"4"}},{"id":2644323,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":126804,"kind":"person","name":"Kirkpatrick Lynn","position":1,"cik":"0001418785","reported_name":"Kirkpatrick Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-07-02T18:11:57.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":284851,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the \"Merger Agreement\") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the \"Issuer\"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and Ensysce Biosciences, Inc., a Delaware corporation (\"Ensysce\"), Merger Sub merged with and into Ensysce (the \"Merger\"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each share of Ensysce common stock was automatically converted into the right to receive a pro rata portion of 17,334,518 shares of the Issuer's common stock."}],"balance_after":284851,"source":{"system":"sec-edgar","filing":"0001192482-21-000618","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1418785/000119248221000618/edgar.xml","form_type":"4"}},{"id":2643899,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":125830,"kind":"person","name":"Martin Steven Robert","position":1,"cik":"0001328822","reported_name":"Martin Steven Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2021-07-02T18:09:34.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":65850,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"The option vests over three years with 1/3 of the total number of shares subject to the option vesting on the first anniversary of the date of grant and 1/36th of the total number of shares subject to the option vesting monthly thereafter, until fully vested on 08/10/2023."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the \"Merger Agreement\") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the \"Issuer\"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and Ensysce Biosciences, Inc., a Delaware corporation (\"Ensysce\"), Merger Sub merged with and into Ensysce (the \"Merger\"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a \"Derivative Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the \"Merger Agreement\") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the \"Issuer\"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and Ensysce Biosciences, Inc., a Delaware corporation (\"Ensysce\"), Merger Sub merged with and into Ensysce (the \"Merger\"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a \"Derivative Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement."}],"balance_after":65850,"derivative":{"exercise_price":3.35,"expiration_date":"2030-08-09","underlying":"Common Stock","underlying_shares":65850},"source":{"system":"sec-edgar","filing":"0001192482-21-000615","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328822/000119248221000615/edgar.xml","form_type":"4"}},{"id":2645328,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":137628,"kind":"person","name":"Wright Richard Chester","position":1,"cik":"0001869634","reported_name":"Wright Richard Chester","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option","published_at":"2021-07-02T18:08:38.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":987750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the \"Merger Agreement\") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the \"Issuer\"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and Ensysce Biosciences, Inc., a Delaware corporation (\"Ensysce\"), Merger Sub merged with and into Ensysce (the \"Merger\"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a \"Derivative Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the \"Merger Agreement\") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the \"Issuer\"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and Ensysce Biosciences, Inc., a Delaware corporation (\"Ensysce\"), Merger Sub merged with and into Ensysce (the \"Merger\"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a \"Derivative Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement."}],"balance_after":987750,"derivative":{"exercise_price":2.59,"expiration_date":"2029-02-28","underlying":"Common Stock","underlying_shares":987750},"source":{"system":"sec-edgar","filing":"0001192482-21-000614","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1869634/000119248221000614/edgar.xml","form_type":"4"}},{"id":2645327,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":137628,"kind":"person","name":"Wright Richard Chester","position":1,"cik":"0001869634","reported_name":"Wright Richard Chester","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option","published_at":"2021-07-02T18:08:38.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":19755,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the \"Merger Agreement\") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the \"Issuer\"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and Ensysce Biosciences, Inc., a Delaware corporation (\"Ensysce\"), Merger Sub merged with and into Ensysce (the \"Merger\"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a \"Derivative Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the \"Merger Agreement\") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the \"Issuer\"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and Ensysce Biosciences, Inc., a Delaware corporation (\"Ensysce\"), Merger Sub merged with and into Ensysce (the \"Merger\"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a \"Derivative Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement."}],"balance_after":19755,"derivative":{"exercise_price":2.59,"expiration_date":"2028-10-01","underlying":"Common Stock","underlying_shares":19755},"source":{"system":"sec-edgar","filing":"0001192482-21-000614","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1869634/000119248221000614/edgar.xml","form_type":"4"}},{"id":2645326,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":137628,"kind":"person","name":"Wright Richard Chester","position":1,"cik":"0001869634","reported_name":"Wright Richard Chester","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option","published_at":"2021-07-02T18:08:38.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":263400,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the \"Merger Agreement\") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the \"Issuer\"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and Ensysce Biosciences, Inc., a Delaware corporation (\"Ensysce\"), Merger Sub merged with and into Ensysce (the \"Merger\"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a \"Derivative Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the \"Merger Agreement\") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the \"Issuer\"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and Ensysce Biosciences, Inc., a Delaware corporation (\"Ensysce\"), Merger Sub merged with and into Ensysce (the \"Merger\"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a \"Derivative Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement."}],"balance_after":263400,"derivative":{"exercise_price":1.83,"expiration_date":"2027-07-01","underlying":"Common Stock","underlying_shares":263400},"source":{"system":"sec-edgar","filing":"0001192482-21-000614","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1869634/000119248221000614/edgar.xml","form_type":"4"}},{"id":2645325,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":137628,"kind":"person","name":"Wright Richard Chester","position":1,"cik":"0001869634","reported_name":"Wright Richard Chester","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option","published_at":"2021-07-02T18:08:38.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":65850,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the \"Merger Agreement\") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the \"Issuer\"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and Ensysce Biosciences, Inc., a Delaware corporation (\"Ensysce\"), Merger Sub merged with and into Ensysce (the \"Merger\"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a \"Derivative Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the \"Merger Agreement\") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the \"Issuer\"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and Ensysce Biosciences, Inc., a Delaware corporation (\"Ensysce\"), Merger Sub merged with and into Ensysce (the \"Merger\"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a \"Derivative Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement."}],"balance_after":65850,"derivative":{"exercise_price":1.83,"expiration_date":"2026-11-01","underlying":"Common Stock","underlying_shares":65850},"source":{"system":"sec-edgar","filing":"0001192482-21-000614","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1869634/000119248221000614/edgar.xml","form_type":"4"}},{"id":2645324,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":137628,"kind":"person","name":"Wright Richard Chester","position":1,"cik":"0001869634","reported_name":"Wright Richard Chester","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option","published_at":"2021-07-02T18:08:38.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":49975,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the \"Merger Agreement\") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the \"Issuer\"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and Ensysce Biosciences, Inc., a Delaware corporation (\"Ensysce\"), Merger Sub merged with and into Ensysce (the \"Merger\"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a \"Derivative Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the \"Merger Agreement\") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the \"Issuer\"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and Ensysce Biosciences, Inc., a Delaware corporation (\"Ensysce\"), Merger Sub merged with and into Ensysce (the \"Merger\"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a \"Derivative Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement."}],"balance_after":49975,"derivative":{"exercise_price":3.21,"expiration_date":"2023-12-21","underlying":"Common Stock","underlying_shares":49975},"source":{"system":"sec-edgar","filing":"0001192482-21-000614","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869634/000119248221000614/edgar.xml","form_type":"4"}},{"id":2644177,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":137608,"kind":"person","name":"Schmidt William K","position":1,"cik":"0001301122","reported_name":"Schmidt William K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option","published_at":"2021-07-02T18:08:04.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":69142,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the \"Merger Agreement\") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the \"Issuer\"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and Ensysce Biosciences, Inc., a Delaware corporation (\"Ensysce\"), Merger Sub merged with and into Ensysce (the \"Merger\"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a \"Derivative Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the \"Merger Agreement\") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the \"Issuer\"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and Ensysce Biosciences, Inc., a Delaware corporation (\"Ensysce\"), Merger Sub merged with and into Ensysce (the \"Merger\"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a \"Derivative Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement."}],"balance_after":69142,"derivative":{"exercise_price":3.22,"expiration_date":"2026-02-04","underlying":"Common Stock","underlying_shares":69142},"source":{"system":"sec-edgar","filing":"0001192482-21-000613","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1301122/000119248221000613/edgar.xml","form_type":"4"}},{"id":2647536,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":43804,"kind":"person","name":"Silvers Daniel B.","position":1,"cik":"0001468195","reported_name":"Silvers Daniel B.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137681,"kind":"organization","name":"Matthews Lane Capital Partners LLC","position":2,"cik":"0001722952","reported_name":"Matthews Lane Capital Partners LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137682,"kind":"organization","name":"MLCP GLL Funding LLC","position":3,"cik":"0001722935","reported_name":"MLCP GLL Funding LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2021-07-01T23:50:59.000Z","date":"2021-06-30","kind":"disposition_to_issuer","acquired":false,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"MLCP GLL Funding LLC"},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Reflects warrants surrendered to the Issuer in connection with the Issuer's business combination pursuant to a warrant surrender agreement, for no consideration."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Reflects warrants surrendered to the Issuer in connection with the Issuer's business combination pursuant to a warrant surrender agreement, for no consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Matthews Lane Capital Partners LLC, a sponsor of the Issuer, is the manager of MLCP GLL Funding LLC, the record holder of the warrants. Mr. Silvers is the managing member of Matthews Lane Capital Partners LLC and disclaims beneficial ownership with respect to the securities except to the extent of his pecuniary interest therein."}],"balance_after":1754497,"derivative":{"exercise_price":11.5,"exercise_date":"2021-07-30","expiration_date":"2026-06-30","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001493152-21-015899","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1468195/000149315221015899/ownership.xml","form_type":"4"}},{"id":2647535,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":43804,"kind":"person","name":"Silvers Daniel B.","position":1,"cik":"0001468195","reported_name":"Silvers Daniel B.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137681,"kind":"organization","name":"Matthews Lane Capital Partners LLC","position":2,"cik":"0001722952","reported_name":"Matthews Lane Capital Partners LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137682,"kind":"organization","name":"MLCP GLL Funding LLC","position":3,"cik":"0001722935","reported_name":"MLCP GLL Funding LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2021-07-01T23:50:59.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":367107,"price":1,"value":367107.0,"ownership":{"direct":false,"nature":"MLCP GLL Funding LLC"},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Reflects warrants acquired at a price of $1.00 per warrant upon the conversion of promissory notes of the Issuer reflecting amounts loaned to the Issuer pursuant to the Issuer's expense advancement agreement, which were convertible into warrants at the holder's option. The warrants are on the same terms as the warrants described in note (1) above."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Reflects warrants acquired at a price of $1.00 per warrant upon the conversion of promissory notes of the Issuer reflecting amounts loaned to the Issuer pursuant to the Issuer's expense advancement agreement, which were convertible into warrants at the holder's option. The warrants are on the same terms as the warrants described in note (1) above."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Matthews Lane Capital Partners LLC, a sponsor of the Issuer, is the manager of MLCP GLL Funding LLC, the record holder of the warrants. Mr. Silvers is the managing member of Matthews Lane Capital Partners LLC and disclaims beneficial ownership with respect to the securities except to the extent of his pecuniary interest therein."}],"balance_after":2004497,"derivative":{"exercise_price":11.5,"exercise_date":"2021-07-30","expiration_date":"2026-06-30","underlying":"Common Stock","underlying_shares":367107},"source":{"system":"sec-edgar","filing":"0001493152-21-015899","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1468195/000149315221015899/ownership.xml","form_type":"4"}},{"id":2647534,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":43804,"kind":"person","name":"Silvers Daniel B.","position":1,"cik":"0001468195","reported_name":"Silvers Daniel B.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137681,"kind":"organization","name":"Matthews Lane Capital Partners LLC","position":2,"cik":"0001722952","reported_name":"Matthews Lane Capital Partners LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137682,"kind":"organization","name":"MLCP GLL Funding LLC","position":3,"cik":"0001722935","reported_name":"MLCP GLL Funding LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2021-07-01T23:50:59.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":1637390,"price":1,"value":1637390.0,"ownership":{"direct":false,"nature":"MLCP GLL Funding LLC"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Reflects warrants of Ensysce Biosciences, Inc., formerly known as Leisure Acquisition Corp. (the \"Issuer\"), which were acquired from the Issuer at a price of $1.00 per warrant in a private placement that closed simultaneously with the closing of the Issuer's initial public offering which were later exchanged for warrants having the same terms, except that they are non-transferable other than to permitted transferees. Pursuant to the terms of the issuance, such warrants were not eligible to become exercisable unless the Issuer consummated its initial business combination which occurred on June 30, 2021. Mr. Silvers served as the Issuer's Chief Executive Officer and Director until the closing of the business combination."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects warrants of Ensysce Biosciences, Inc., formerly known as Leisure Acquisition Corp. (the \"Issuer\"), which were acquired from the Issuer at a price of $1.00 per warrant in a private placement that closed simultaneously with the closing of the Issuer's initial public offering which were later exchanged for warrants having the same terms, except that they are non-transferable other than to permitted transferees. Pursuant to the terms of the issuance, such warrants were not eligible to become exercisable unless the Issuer consummated its initial business combination which occurred on June 30, 2021. Mr. Silvers served as the Issuer's Chief Executive Officer and Director until the closing of the business combination."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Matthews Lane Capital Partners LLC, a sponsor of the Issuer, is the manager of MLCP GLL Funding LLC, the record holder of the warrants. Mr. Silvers is the managing member of Matthews Lane Capital Partners LLC and disclaims beneficial ownership with respect to the securities except to the extent of his pecuniary interest therein."}],"balance_after":1637390,"derivative":{"exercise_price":11.5,"exercise_date":"2021-07-30","expiration_date":"2026-06-30","underlying":"Common Stock","underlying_shares":1637390},"source":{"system":"sec-edgar","filing":"0001493152-21-015899","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1468195/000149315221015899/ownership.xml","form_type":"4"}},{"id":2648583,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":55688,"kind":"person","name":"WEIL A LORNE","position":1,"cik":"0000921873","reported_name":"WEIL A LORNE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2021-07-01T19:56:22.000Z","date":"2021-06-30","kind":"disposition_to_issuer","acquired":false,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Hydra Management LLC"},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Reflects warrants surrendered to the Issuer in connection with the Issuer's business combination pursuant to a warrant surrender agreement, for no consideration."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Reflects warrants surrendered to the Issuer in connection with the Issuer's business combination pursuant to a warrant surrender agreement, for no consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. Weil is the managing member of Hydra LAC LLC and the sole member of Hydra Management LLC and disclaims beneficial ownership with respect to the securities except to the extent of his pecuniary interest therein."}],"balance_after":137895,"derivative":{"exercise_price":11.5,"exercise_date":"2021-07-30","expiration_date":"2026-06-30","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001493152-21-015905","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/921873/000149315221015905/ownership.xml","form_type":"4"}},{"id":2648582,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":55688,"kind":"person","name":"WEIL A LORNE","position":1,"cik":"0000921873","reported_name":"WEIL A LORNE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2021-07-01T19:56:22.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":387895,"price":1,"value":387895.0,"ownership":{"direct":false,"nature":"Hydra Management LLC"},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Reflects warrants acquired at a price of $1.00 per warrant upon the conversion of promissory notes of the Issuer held by Hydra Management LLC reflecting amounts loaned to the Issuer pursuant to the Issuer's expense advancement agreement, which were convertible into warrants at the holder's option. The warrants are on the same terms as the warrants described in note (1) above."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Reflects warrants acquired at a price of $1.00 per warrant upon the conversion of promissory notes of the Issuer held by Hydra Management LLC reflecting amounts loaned to the Issuer pursuant to the Issuer's expense advancement agreement, which were convertible into warrants at the holder's option. The warrants are on the same terms as the warrants described in note (1) above."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. Weil is the managing member of Hydra LAC LLC and the sole member of Hydra Management LLC and disclaims beneficial ownership with respect to the securities except to the extent of his pecuniary interest therein."}],"balance_after":387895,"derivative":{"exercise_price":11.5,"exercise_date":"2021-07-30","expiration_date":"2026-06-30","underlying":"Common Stock","underlying_shares":387895},"source":{"system":"sec-edgar","filing":"0001493152-21-015905","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/921873/000149315221015905/ownership.xml","form_type":"4"}},{"id":2648581,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":55688,"kind":"person","name":"WEIL A LORNE","position":1,"cik":"0000921873","reported_name":"WEIL A LORNE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2021-07-01T19:56:22.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":1000000,"price":1,"value":1000000.0,"ownership":{"direct":false,"nature":"Hydra LAC LLC"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Reflects warrants of Ensysce Biosciences, Inc., formerly known as Leisure Acquisition Corp. (the \"Issuer\"), which were acquired from the Issuer at a price of $1.00 per warrant (730,110 warrants by Mr. Weil at a cost of $730,110 and 1,000,000 warrants by Hydra LAC LLC (an entity affiliated with Mr. Weil) at a cost of $1,000,000) in a private placement that closed simultaneously with the closing of the Issuer's initial public offering which were later exchanged for warrants having the same terms, except that they are non-transferable other than to permitted transferees. Pursuant to the terms of the issuance, such warrants were not eligible to become exercisable unless the Issuer consummated its initial business combination which occurred on June 30, 2021. Mr. Weil served as the Issuer's Executive Chairman until the closing of the business combination."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects warrants of Ensysce Biosciences, Inc., formerly known as Leisure Acquisition Corp. (the \"Issuer\"), which were acquired from the Issuer at a price of $1.00 per warrant (730,110 warrants by Mr. Weil at a cost of $730,110 and 1,000,000 warrants by Hydra LAC LLC (an entity affiliated with Mr. Weil) at a cost of $1,000,000) in a private placement that closed simultaneously with the closing of the Issuer's initial public offering which were later exchanged for warrants having the same terms, except that they are non-transferable other than to permitted transferees. Pursuant to the terms of the issuance, such warrants were not eligible to become exercisable unless the Issuer consummated its initial business combination which occurred on June 30, 2021. Mr. Weil served as the Issuer's Executive Chairman until the closing of the business combination."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. Weil is the managing member of Hydra LAC LLC and the sole member of Hydra Management LLC and disclaims beneficial ownership with respect to the securities except to the extent of his pecuniary interest therein."}],"balance_after":1000000,"derivative":{"exercise_price":11.5,"exercise_date":"2021-07-30","expiration_date":"2026-06-30","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0001493152-21-015905","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/921873/000149315221015905/ownership.xml","form_type":"4"}},{"id":2648580,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":55688,"kind":"person","name":"WEIL A LORNE","position":1,"cik":"0000921873","reported_name":"WEIL A LORNE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2021-07-01T19:56:22.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":730110,"price":1,"value":730110.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Reflects warrants of Ensysce Biosciences, Inc., formerly known as Leisure Acquisition Corp. (the \"Issuer\"), which were acquired from the Issuer at a price of $1.00 per warrant (730,110 warrants by Mr. Weil at a cost of $730,110 and 1,000,000 warrants by Hydra LAC LLC (an entity affiliated with Mr. Weil) at a cost of $1,000,000) in a private placement that closed simultaneously with the closing of the Issuer's initial public offering which were later exchanged for warrants having the same terms, except that they are non-transferable other than to permitted transferees. Pursuant to the terms of the issuance, such warrants were not eligible to become exercisable unless the Issuer consummated its initial business combination which occurred on June 30, 2021. Mr. Weil served as the Issuer's Executive Chairman until the closing of the business combination."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects warrants of Ensysce Biosciences, Inc., formerly known as Leisure Acquisition Corp. (the \"Issuer\"), which were acquired from the Issuer at a price of $1.00 per warrant (730,110 warrants by Mr. Weil at a cost of $730,110 and 1,000,000 warrants by Hydra LAC LLC (an entity affiliated with Mr. Weil) at a cost of $1,000,000) in a private placement that closed simultaneously with the closing of the Issuer's initial public offering which were later exchanged for warrants having the same terms, except that they are non-transferable other than to permitted transferees. Pursuant to the terms of the issuance, such warrants were not eligible to become exercisable unless the Issuer consummated its initial business combination which occurred on June 30, 2021. Mr. Weil served as the Issuer's Executive Chairman until the closing of the business combination."}],"balance_after":730110,"derivative":{"exercise_price":11.5,"exercise_date":"2021-07-30","expiration_date":"2026-06-30","underlying":"Common Stock","underlying_shares":730110},"source":{"system":"sec-edgar","filing":"0001493152-21-015905","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921873/000149315221015905/ownership.xml","form_type":"4"}},{"id":2647082,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":68370,"kind":"person","name":"Peng George","position":1,"cik":"0001651293","reported_name":"Peng George","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former officer"}}],"security":"Warrants","published_at":"2021-07-01T19:54:47.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":15000,"price":1,"value":15000.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Reflects warrants of Ensysce Biosciences, Inc., formerly known as Leisure Acquisition Corp. (the \"Issuer\"), which were acquired from the Issuer at a price of $1.00 per warrant in a private placement that closed simultaneously with the closing of the Issuer's initial public offering which were later exchanged for warrants having the same terms, except that they are non-transferable other than to permitted transferees. Pursuant to the terms of the issuance, such warrants were not eligible to become exercisable unless the Issuer consummated its initial business combination which occurred on June 30, 2021. Mr. Peng served as the Issuer's Chief Financial Officer until the closing of the business combination."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects warrants of Ensysce Biosciences, Inc., formerly known as Leisure Acquisition Corp. (the \"Issuer\"), which were acquired from the Issuer at a price of $1.00 per warrant in a private placement that closed simultaneously with the closing of the Issuer's initial public offering which were later exchanged for warrants having the same terms, except that they are non-transferable other than to permitted transferees. Pursuant to the terms of the issuance, such warrants were not eligible to become exercisable unless the Issuer consummated its initial business combination which occurred on June 30, 2021. Mr. Peng served as the Issuer's Chief Financial Officer until the closing of the business combination."}],"balance_after":15000,"derivative":{"exercise_price":11.5,"exercise_date":"2021-07-30","expiration_date":"2026-06-30","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001493152-21-015903","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1651293/000149315221015903/ownership.xml","form_type":"4"}},{"id":2647604,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":137683,"kind":"person","name":"Carrera Eric","position":1,"cik":"0001657726","reported_name":"Carrera Eric","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former officer"}}],"security":"Warrants","published_at":"2021-07-01T19:52:16.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":30000,"price":1,"value":30000.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Reflects warrants of Ensysce Biosciences, Inc., formerly known as Leisure Acquisition Corp. (the \"Issuer\"), which were acquired from the Issuer at a price of $1.00 per warrant in a private placement that closed simultaneously with the closing of the Issuer's initial public offering which were later exchanged for warrants having the same terms, except that they are non-transferable other than to permitted transferees. Pursuant to the terms of the issuance, such warrants were not eligible to become exercisable unless the Issuer consummated its initial business combination which occurred on June 30, 2021. Mr. Carrera served as the Issuer's Senior Vice President of Finance and Business Development until the closing of the business combination."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects warrants of Ensysce Biosciences, Inc., formerly known as Leisure Acquisition Corp. (the \"Issuer\"), which were acquired from the Issuer at a price of $1.00 per warrant in a private placement that closed simultaneously with the closing of the Issuer's initial public offering which were later exchanged for warrants having the same terms, except that they are non-transferable other than to permitted transferees. Pursuant to the terms of the issuance, such warrants were not eligible to become exercisable unless the Issuer consummated its initial business combination which occurred on June 30, 2021. Mr. Carrera served as the Issuer's Senior Vice President of Finance and Business Development until the closing of the business combination."}],"balance_after":30000,"derivative":{"exercise_price":11.5,"exercise_date":"2021-07-30","expiration_date":"2026-06-30","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001493152-21-015901","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1657726/000149315221015901/ownership.xml","form_type":"4"}},{"id":103795,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":2815,"kind":"organization","name":"MORGAN STANLEY","symbol":"MS","position":1,"cik":"0000895421","reported_name":"MORGAN STANLEY","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-06-23T21:39:59.000Z","date":"2020-06-19","kind":"sale","acquired":false,"shares":776290,"ownership":{"direct":false,"nature":"By Subsidiary"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Pursuant to the Issuer's Extension Amendment and the Trust Amendment proposals set forth in the Issuer's Proxy Statement filed with the Commission on June 2, 2020, the Issuer's public stockholders were offered the opportunity to redeem their shares in exchange for their pro rata portion of the funds available in the trust account at the time of the Special Meeting on June 23, 2020, which elections became irrevocable on June 19, 2020.   Morgan Stanley elected to redeem its shares and will receive its per-share pro rata portion of the trust account, estimated by the Issuer to be approximately $10.44."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Issuer's Extension Amendment and the Trust Amendment proposals set forth in the Issuer's Proxy Statement filed with the Commission on June 2, 2020, the Issuer's public stockholders were offered the opportunity to redeem their shares in exchange for their pro rata portion of the funds available in the trust account at the time of the Special Meeting on June 23, 2020, which elections became irrevocable on June 19, 2020.   Morgan Stanley elected to redeem its shares and will receive its per-share pro rata portion of the trust account, estimated by the Issuer to be approximately $10.44."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000925421-20-000259","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/895421/000092542120000259/edgar.xml","form_type":"4"}},{"id":4097516,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":118003,"kind":"organization","name":"HG Vora Capital Management, LLC","position":1,"cik":"0001525362","reported_name":"HG Vora Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-01-17T22:39:39.000Z","date":"2018-01-15","kind":"other","acquired":false,"shares":375000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"As contemplated by the securities subscription agreement between HG Vora Special Opportunities and the Company, 375,000 shares held by HG Vora Special Opportunities were forfeited since the underwriters did not exercise their overallotment option in the Company's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As contemplated by the securities subscription agreement between HG Vora Special Opportunities and the Company, 375,000 shares held by HG Vora Special Opportunities were forfeited since the underwriters did not exercise their overallotment option in the Company's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Securities owned directly by HG Vora Special Opportunities Master Fund, Ltd. (\"HG Vora Special Opportunities\"). HG Vora Capital Management, LLC (\"HG Vora Capital) is a registered investment adviser under the Investment Advisers Act of 1940, as amended, and acts as an investment adviser to certain investment entities. HG Vora Capital, as investment manager of HG Vora Special Opportunities, may be deemed to beneficially own the securities owned directly by HG Vora Special Opportunities."}],"balance_after":3462500,"source":{"system":"sec-edgar","filing":"0001615774-18-000390","document":"s108738_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1525362/000161577418000390/s108738_form4.xml","form_type":"4"}},{"id":4097515,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":118003,"kind":"organization","name":"HG Vora Capital Management, LLC","position":1,"cik":"0001525362","reported_name":"HG Vora Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-01-17T22:39:39.000Z","date":"2017-12-01","kind":"purchase","acquired":true,"shares":1000000,"price":10,"value":10000000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Securities owned directly by HG Vora Special Opportunities Master Fund, Ltd. (\"HG Vora Special Opportunities\"). HG Vora Capital Management, LLC (\"HG Vora Capital) is a registered investment adviser under the Investment Advisers Act of 1940, as amended, and acts as an investment adviser to certain investment entities. HG Vora Capital, as investment manager of HG Vora Special Opportunities, may be deemed to beneficially own the securities owned directly by HG Vora Special Opportunities."}],"balance_after":3837500,"source":{"system":"sec-edgar","filing":"0001615774-18-000390","document":"s108738_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1525362/000161577418000390/s108738_form4.xml","form_type":"4"}},{"id":4097814,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":43804,"kind":"person","name":"Silvers Daniel B.","position":1,"cik":"0001468195","reported_name":"Silvers Daniel B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}},{"id":137681,"kind":"organization","name":"Matthews Lane Capital Partners LLC","position":2,"cik":"0001722952","reported_name":"Matthews Lane Capital Partners LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Sponsors of the Co."}},{"id":137682,"kind":"organization","name":"MLCP GLL Funding LLC","position":3,"cik":"0001722935","reported_name":"MLCP GLL Funding LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Sponsor Affiliate of the Co."}}],"security":"Common Stock","published_at":"2018-01-17T22:18:54.000Z","date":"2018-01-15","kind":"other","acquired":false,"shares":171832,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"As contemplated by the securities subscription agreement between each reporting person and the Company, 171,832 shares held by MLCP GLL Funding LLC, an affiliate of a sponsor of the Company (the \"Sponsor Affiliate\") and Matthews Lane Capital Partners LLC, a sponsor of the Company (the \"Sponsor\"), were forfeited since the underwriters did not exercise their overallotment option in the Company's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"As contemplated by the securities subscription agreement between each reporting person and the Company, 171,832 shares held by MLCP GLL Funding LLC, an affiliate of a sponsor of the Company (the \"Sponsor Affiliate\") and Matthews Lane Capital Partners LLC, a sponsor of the Company (the \"Sponsor\"), were forfeited since the underwriters did not exercise their overallotment option in the Company's initial public offering."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents 887,127 shares of common stock held by the Sponsor Affiliate. Represents 241,243 shares of common stock held by the Sponsor. The shares held by the Sponsor Affiliate and the Sponsor are beneficially owned by\nDaniel B. Silvers, who has sole voting and dispositive power over the shares held by the Sponsor Affiliate and the Sponsor. Mr. Silvers owns all of the membership interests in the Sponsor Affiliate and the Sponsor. Mr. Silvers disclaims beneficial ownership over any securities owned by the Sponsor and the Sponsor Affiliate in which he does not have any pecuniary interest."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents 887,127 shares of common stock held by the Sponsor Affiliate. Represents 241,243 shares of common stock held by the Sponsor. The shares held by the Sponsor Affiliate and the Sponsor are beneficially owned by\nDaniel B. Silvers, who has sole voting and dispositive power over the shares held by the Sponsor Affiliate and the Sponsor. Mr. Silvers owns all of the membership interests in the Sponsor Affiliate and the Sponsor. Mr. Silvers disclaims beneficial ownership over any securities owned by the Sponsor and the Sponsor Affiliate in which he does not have any pecuniary interest."}],"balance_after":1128370,"source":{"system":"sec-edgar","filing":"0001615774-18-000382","document":"s108737_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1468195/000161577418000382/s108737_form4.xml","form_type":"4"}},{"id":4098453,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":55688,"kind":"person","name":"WEIL A LORNE","position":1,"cik":"0000921873","reported_name":"WEIL A LORNE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}},{"id":170275,"kind":"organization","name":"Hydra LAC, LLC","position":2,"cik":"0001723195","reported_name":"Hydra LAC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Sponsor Affiliate of the Co."}}],"security":"Common Stock","published_at":"2018-01-17T17:35:11.000Z","date":"2018-01-15","kind":"other","acquired":false,"shares":132158,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"As contemplated by the securities subscription agreement between such reporting person and the Company, 132,158 shares held by Hydra LAC, LLC, an affiliate of a sponsor of the Company (the \"Sponsor Affiliate\"), were forfeited since the underwriters did not exercise their overallotment option in the Company's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As contemplated by the securities subscription agreement between such reporting person and the Company, 132,158 shares held by Hydra LAC, LLC, an affiliate of a sponsor of the Company (the \"Sponsor Affiliate\"), were forfeited since the underwriters did not exercise their overallotment option in the Company's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares of common stock held by the Sponsor Affiliate. The shares held by the Sponsor Affiliate are beneficially owned by A. Lorne Weil, who has sole voting and dispositive power over the shares held by the Sponsor Affiliate. Mr. Weil owns all of the membership interests in the Sponsor Affiliate. Mr. Weil disclaims beneficial ownership over any securities owned by the Sponsor Affiliate in which he does not have any pecuniary interest."}],"balance_after":867842,"source":{"system":"sec-edgar","filing":"0001615774-18-000388","document":"s108741_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/921873/000161577418000388/s108741_form4.xml","form_type":"4"}},{"id":4098452,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":55688,"kind":"person","name":"WEIL A LORNE","position":1,"cik":"0000921873","reported_name":"WEIL A LORNE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}},{"id":170275,"kind":"organization","name":"Hydra LAC, LLC","position":2,"cik":"0001723195","reported_name":"Hydra LAC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Sponsor Affiliate of the Co."}}],"security":"Common Stock","published_at":"2018-01-17T17:35:11.000Z","date":"2018-01-15","kind":"other","acquired":false,"shares":40645,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"As contemplated by the securities subscription agreement between such reporting person and the Company, 40,645 shares held by Mr. Weil were forfeited since the underwriters did not exercise their overallotment option in the Company's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"As contemplated by the securities subscription agreement between such reporting person and the Company, 40,645 shares held by Mr. Weil were forfeited since the underwriters did not exercise their overallotment option in the Company's initial public offering."}],"balance_after":266900,"source":{"system":"sec-edgar","filing":"0001615774-18-000388","document":"s108741_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921873/000161577418000388/s108741_form4.xml","form_type":"4"}},{"id":4097413,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":68370,"kind":"person","name":"Peng George","position":1,"cik":"0001651293","reported_name":"Peng George","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-01-17T17:26:44.000Z","date":"2018-01-15","kind":"other","acquired":false,"shares":13251,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"As contemplated by the securities subscription agreement between the reporting person and the Company, 13,251 shares held by Mr. Peng were forfeited since the underwriters did not exercise their overallotment option in the Company's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"As contemplated by the securities subscription agreement between the reporting person and the Company, 13,251 shares held by Mr. Peng were forfeited since the underwriters did not exercise their overallotment option in the Company's initial public offering."}],"balance_after":87014,"source":{"system":"sec-edgar","filing":"0001615774-18-000386","document":"s108740_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1651293/000161577418000386/s108740_form4.xml","form_type":"4"}},{"id":4097927,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":137683,"kind":"person","name":"Carrera Eric","position":1,"cik":"0001657726","reported_name":"Carrera Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Common Stock","published_at":"2018-01-17T17:21:17.000Z","date":"2018-01-15","kind":"other","acquired":false,"shares":8330,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"As contemplated by the securities subscription agreement between the reporting person and the Company, 8,330 shares held by Mr. Carrera were forfeited since the underwriters did not exercise their overallotment option in the Company's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"As contemplated by the securities subscription agreement between the reporting person and the Company, 8,330 shares held by Mr. Carrera were forfeited since the underwriters did not exercise their overallotment option in the Company's initial public offering."}],"balance_after":54701,"source":{"system":"sec-edgar","filing":"0001615774-18-000384","document":"s108739_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1657726/000161577418000384/s108739_form4.xml","form_type":"4"}},{"id":4141931,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":43804,"kind":"person","name":"Silvers Daniel B.","position":1,"cik":"0001468195","reported_name":"Silvers Daniel B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}},{"id":137681,"kind":"organization","name":"Matthews Lane Capital Partners LLC","position":2,"cik":"0001722952","reported_name":"Matthews Lane Capital Partners LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Sponsor of the Company"}},{"id":137682,"kind":"organization","name":"MLCP GLL Funding LLC","position":3,"cik":"0001722935","reported_name":"MLCP GLL Funding LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Sponsor Affiliate of the Co."}}],"security":"Common Stock","published_at":"2017-12-05T23:57:12.000Z","date":"2017-12-05","kind":"other","acquired":false,"shares":359869,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"As contemplated by the securities subscription agreement between each reporting person and the Company, 359,869 shares held by MLCP GLL Funding LLC, an affiliate of a sponsor of the Company (the \"Sponsor Affiliate\") and Matthews Lane Capital Partners LLC, a sponsor of the Company (the \"Sponsor\"), were forfeited upon consummation of the Company's initial public offering for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"As contemplated by the securities subscription agreement between each reporting person and the Company, 359,869 shares held by MLCP GLL Funding LLC, an affiliate of a sponsor of the Company (the \"Sponsor Affiliate\") and Matthews Lane Capital Partners LLC, a sponsor of the Company (the \"Sponsor\"), were forfeited upon consummation of the Company's initial public offering for no consideration."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes an aggregate of 171,833 shares held by the Sponsor Affiliate and the Sponsor that are subject to forfeiture to the extent that the underwriters' overallotment in the Company's initial public offering is not fully exercised."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents 1,022,222 shares of common stock held by the Sponsor Affiliate. Represents 277,980 shares of common stock held by the Sponsor. The shares held by the Sponsor Affiliate and the Sponsor are beneficially owned by Daniel B. Silvers, who has sole voting and dispositive power over the shares held by the Sponsor Affiliate and the Sponsor. Mr. Silvers owns all of the membership interests in the Sponsor Affiliate and the Sponsor. Mr. Silvers disclaims beneficial ownership over any securities owned by the Sponsor and the Sponsor Affiliate in which he does not have any pecuniary interest."}],"balance_after":1300202,"source":{"system":"sec-edgar","filing":"0001144204-17-062472","document":"tv480824_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1468195/000114420417062472/tv480824_4.xml","form_type":"4"}},{"id":4141488,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":118003,"kind":"organization","name":"HG Vora Capital Management, LLC","position":1,"cik":"0001525362","reported_name":"HG Vora Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-05T23:56:32.000Z","date":"2017-12-05","kind":"other","acquired":false,"shares":718750,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"As contemplated by the securities subscription agreement between HG Vora Special Opportunities Master Fund, Ltd. (\"HG Vora Special Opportunities\") and the Company, 718,750 shares held by HG Vora Special Opportunities were forfeited upon consummation of the Company's initial public offering for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"As contemplated by the securities subscription agreement between HG Vora Special Opportunities Master Fund, Ltd. (\"HG Vora Special Opportunities\") and the Company, 718,750 shares held by HG Vora Special Opportunities were forfeited upon consummation of the Company's initial public offering for no consideration."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 375,000 shares beneficially owned by HG Vora Capital Management, LLC (\"HG Vora Capital\") that are subject to forfeiture to the extent the underwriters' overallotment option in the Company's initial public offering is not fully exercised."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Securities owned directly by HG Vora Special Opportunities. HG Vora Capital is a registered investment adviser under the Investment Advisers Act of 1940, as amended, and acts as an investment adviser to certain investment entities. HG Vora Capital, as investment manager of HG Vora Special Opportunities, may be deemed to beneficially own the securities owned directly by HG Vora Special Opportunities."}],"balance_after":2837500,"source":{"system":"sec-edgar","filing":"0001144204-17-062470","document":"tv480820_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1525362/000114420417062470/tv480820_4.xml","form_type":"4"}},{"id":4143073,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":55688,"kind":"person","name":"WEIL A LORNE","position":1,"cik":"0000921873","reported_name":"WEIL A LORNE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}},{"id":170275,"kind":"organization","name":"Hydra LAC, LLC","position":2,"cik":"0001723195","reported_name":"Hydra LAC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Sponsor Affiliate of the Co."}}],"security":"Common Stock","published_at":"2017-12-05T18:56:57.000Z","date":"2017-12-05","kind":"other","acquired":false,"shares":169517,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"As contemplated by the securities subscription agreement between such reporting person and the Company, 169,517 shares held by Hydra LAC, LLC, an affiliate of a sponsor of the Company (the \"Sponsor Affiliate\"), were forfeited upon consummation of the Company's initial public offering for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"As contemplated by the securities subscription agreement between such reporting person and the Company, 169,517 shares held by Hydra LAC, LLC, an affiliate of a sponsor of the Company (the \"Sponsor Affiliate\"), were forfeited upon consummation of the Company's initial public offering for no consideration."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes an aggregate of 132,159 shares held by the Sponsor Affiliate that are subject to forfeiture to the extent that the underwriters' overallotment option in the Company's initial public offering is not exercised."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares of common stock held by the Sponsor Affiliate. The shares held by the Sponsor Affiliate are beneficially owned by A. Lorne Weil, who has sole voting and dispositive power over the shares held by the Sponsor Affiliate. Mr. Weil owns all of the membership interests in the Sponsor Affiliate. Mr. Weil disclaims beneficial ownership over any securities owned by the Sponsor Affiliate in which he does not have any pecuniary interest."}],"balance_after":1000000,"source":{"system":"sec-edgar","filing":"0001144204-17-062471","document":"tv480821_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/921873/000114420417062471/tv480821_4.xml","form_type":"4"}},{"id":4143072,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":55688,"kind":"person","name":"WEIL A LORNE","position":1,"cik":"0000921873","reported_name":"WEIL A LORNE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}},{"id":170275,"kind":"organization","name":"Hydra LAC, LLC","position":2,"cik":"0001723195","reported_name":"Hydra LAC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Sponsor Affiliate of the Co."}}],"security":"Common Stock","published_at":"2017-12-05T18:56:57.000Z","date":"2017-12-05","kind":"other","acquired":false,"shares":187166,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"As contemplated by the securities subscription agreement between such reporting person and the Company, 187,166 shares held by Mr. Weil were forfeited upon consummation of the Company's initial public offering for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"As contemplated by the securities subscription agreement between such reporting person and the Company, 187,166 shares held by Mr. Weil were forfeited upon consummation of the Company's initial public offering for no consideration."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes an aggregate of 40,645 shares held by Mr. Weil that are subject to forfeiture to the extent that the underwriters' overallotment option in the Company's initial public offering is not exercised."}],"balance_after":307545,"source":{"system":"sec-edgar","filing":"0001144204-17-062471","document":"tv480821_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921873/000114420417062471/tv480821_4.xml","form_type":"4"}},{"id":4142120,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":137683,"kind":"person","name":"Carrera Eric","position":1,"cik":"0001657726","reported_name":"Carrera Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Common Stock","published_at":"2017-12-05T18:56:14.000Z","date":"2017-12-05","kind":"other","acquired":false,"shares":1465,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"As contemplated by the securities subscription agreement between the reporting person and the Company, 1,465 shares held by Mr. Carrera were forfeited upon consummation of the Company's initial public offering for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"As contemplated by the securities subscription agreement between the reporting person and the Company, 1,465 shares held by Mr. Carrera were forfeited upon consummation of the Company's initial public offering for no consideration."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes an aggregate of 8,330 shares held by Mr. Carrera that are subject to forfeiture to the extent that the underwriters' overallotment option in the Company's initial public offering is not fully exercised."}],"balance_after":63031,"source":{"system":"sec-edgar","filing":"0001144204-17-062469","document":"tv480819_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1657726/000114420417062469/tv480819_4.xml","form_type":"4"}},{"id":4141375,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":68370,"kind":"person","name":"Peng George","position":1,"cik":"0001651293","reported_name":"Peng George","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-12-05T18:55:56.000Z","date":"2017-12-05","kind":"other","acquired":false,"shares":733,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"As contemplated by the securities subscription agreement between the reporting person and the Company, 733 shares held by Mr. Peng were forfeited upon consummation of the Company's initial public offering for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"As contemplated by the securities subscription agreement between the reporting person and the Company, 733 shares held by Mr. Peng were forfeited upon consummation of the Company's initial public offering for no consideration."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes an aggregate of 13,251 shares held by Mr. Peng that are subject to forfeiture to the extent that the underwriters' overallotment option in the Company's initial public offering is not fully exercised."}],"balance_after":100265,"source":{"system":"sec-edgar","filing":"0001144204-17-062468","document":"tv480818_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1651293/000114420417062468/tv480818_4.xml","form_type":"4"}}]}